MOA Life Plus Co. Ltd.
Financials
Valuation Metrics
MOA Life Plus Co. Ltd.'s Market Cap is ₩100B. At end of 2025 it was ₩748B. Ranked #2403 of 2,421 in KR market (top 99%), #1625 of 1,640 on KOSDAQ (top 99%), #230 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 100%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 10.04B KRW | KR#2,403/2,421 Sec#230/231 |
| Revenue | 10.46B KRW | KR#2,285/2,421 Sec#176/231 |
| Net Income | -13.71B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 32.47B KRW | KR#2,321/2,421 Sec#218/231 |
| Net Assets | 24.19B KRW | KR#2,240/2,421 Sec#208/231 |
| Employees | 59 | KR#1,975/2,421 Sec#174/231 |
| Value | ||
| P/B | 0.41x | KR#610/2,421 Sec#20/231 |
| P/S | 0.96x | KR#1,361/2,421 Sec#81/231 |
| FCF Yield | -60.56% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -56.69% | KR#2,296/2,421 Sec#202/231 |
| ROA | -42.22% | KR#2,352/2,421 Sec#213/231 |
| Op. Margin | -65.61% | KR#2,265/2,421 Sec#163/231 |
| Revenue Growth | -13.98% | KR#2,018/2,421 Sec#182/231 |
| Financial Health | ||
| Debt Ratio | 34.26% | KR#673/2,421 Sec#78/231 |
| Total Debt | 10.89B KRW | KR#1,596/2,421 Sec#143/231 |
| FCF | -6.08B KRW | KR#1,550/2,421 Sec#122/231 |
| Cash | 623.2M KRW | KR#2,359/2,421 Sec#223/231 |
| Current Ratio | 2.07x | KR#841/2,421 Sec#94/231 |
| Performance | ||
| 1Y Return | -84.82% | KR#2,368/2,421 Sec#228/231 |
| 1M Return | -31.81% | KR#2,361/2,421 Sec#224/231 |
| From 52W High | -87.43% | KR#2,398/2,421 Sec#230/231 |
| 1Y MDD | -87.14% | KR#2,391/2,421 Sec#229/231 |
| Trading | ||
| Volume | 165,477 shares | KR#551/2,421 Sec#37/231 |
| Trading Value | 78.5M KRW | KR#1,662/2,421 Sec#167/231 |
| Foreign Own. | 0.00% | KR—/2,421 Sec—/231 |
| Per Share | ||
| EPS | -650 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,147 KRW | KR#2,274/2,421 Sec#205/231 |
Company Info
Established in 1999 based on poly-gamma-glutamic acid source technology, the company is a bio new drug development firm listed on KOSDAQ in 2016. Utilizing HumaMAX and MucoMAX platforms, it focuses on new drug development and operates in health functional foods, functional cosmetics, pet care, and pharmaceutical distribution. The company holds a pipeline for rare disease treatments and manufactures and distributes health functional foods and functional cosmetics using immune-boosting functional ingredients.